Literature DB >> 6402520

Protease phenotypes of Pseudomonas aeruginosa isolated from patients with cystic fibrosis.

K S Jagger, D R Bahner, R L Warren.   

Abstract

The protease phenotypes expressed by isolates of Pseudomonas aeruginosa from cystic fibrosis (CF) patients were evaluated. The majority of isolates tested produced elastase (65%) or alkaline protease (64%) or both. The mucoid phenotype expressed by many CF isolates of P. aeruginosa did not absolutely restrict the expression of protease activity, although a higher percentage of nonmucoid isolates was proteolytic. When isolates from CF patients chronically infected with P. aeruginosa were compared to isolates from CF patients colonized with this organism, both groups were found to contain comparable percentages of elastase-producing strains and mucoid strains. However, the group of isolates from colonized patients contained a higher percentage of strains producing alkaline protease and expressing general protease activity. In addition, the group of isolates from chronically infected patients contained more weakly proteolytic isolates than either the group from colonized CF patients or a group of isolates from pediatric patients without CF. These data suggest that protease production may be important in the initial colonization of the respiratory tract of CF patients by P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402520      PMCID: PMC272573          DOI: 10.1128/jcm.17.1.55-59.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Growth of Pseudomonas aeruginosa in normal and burned skin extract: role of extracellular proteases.

Authors:  J F Cicmanec; I A Holder
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

2.  Correlation of proteolytic activity of Pseudomonas aeruginosa with site of isolation.

Authors:  J M Janda; S Atang-Nomo; E J Bottone; E P Desmond
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

3.  Production of alkaline protease by Pseudomonas aeruginosa.

Authors:  S J Cryz; B H Iglewski
Journal:  J Clin Microbiol       Date:  1980-07       Impact factor: 5.948

4.  INfluence of Pseudomonas aeruginosa proteases on prothrombin, plasminogen and fibrinogen.

Authors:  G Pulverer; Z Wegrzynowicz; H L Ko; J Jeljaszewicz
Journal:  Zentralbl Bakteriol A       Date:  1980

5.  Antimicrobial susceptibility of mucoid Pseudomonas aeruginosa and their spontaneously occurring non-mucoid derivatives.

Authors:  S M Markowitz; F L Macrina; P V Phibbs
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

6.  Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma alpha 1-proteinase inhibitor.

Authors:  K Morihara; H Tsuzuki; K Oda
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

7.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

8.  Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre.

Authors:  N Høiby; K Rosendal
Journal:  Acta Pathol Microbiol Scand B       Date:  1980-06

9.  Purification and characterization of exocellular proteases produced by a clinical isolate and a laboratory strain of Pseudomonas aeruginosa.

Authors:  S E Jensen; L Phillippe; J Teng Tseng; G W Stemke; J N Campbell
Journal:  Can J Microbiol       Date:  1980-01       Impact factor: 2.419

10.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors.

Authors:  I A Holder; C G Haidaris
Journal:  Can J Microbiol       Date:  1979-05       Impact factor: 2.419

View more
  25 in total

Review 1.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

2.  Disruption of respiratory cilia by proteases including those of Pseudomonas aeruginosa.

Authors:  S T Hingley; A T Hastie; F Kueppers; M L Higgins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

3.  Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections.

Authors:  P Visca; F Chiarini; A Mansi; C Vetriani; L Serino; N Orsi
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

4.  Secretion of proteases by Pseudomonas aeruginosa biofilms exposed to ciprofloxacin.

Authors:  Ewa Ołdak; Elzbieta A Trafny
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Fegan; P Francis; A C Hayward; G H Davis; J A Fuerst
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Purification and characterization of an active fragment of the LasA protein from Pseudomonas aeruginosa: enhancement of elastase activity.

Authors:  J E Peters; D R Galloway
Journal:  J Bacteriol       Date:  1990-05       Impact factor: 3.490

7.  Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase.

Authors:  B K Pedersen; A Kharazmi
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

8.  Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence.

Authors:  A Kharazmi; N Høiby; G Döring; N H Valerius
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

Review 9.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

10.  Effects of FP2 and a mercury resistance plasmid from Pseudomonas aeruginosa PA103 on exoenzyme production.

Authors:  J Johnson; R L Warren; A A Branstrom
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.